Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon α in mice and guinea pigs

Du, Yijun; Dai, Jianjun; Li, Yufeng; Li, Congzhi; Qi, Jing; Duan, Shuyi; Jiang, Ping

doi:10.1016/j.vetimm.2008.04.011

Cited by 10 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been isolated reports mentioning assessment of the activity of certain anti‐microbial agents against FMDV in GP, but these are unavailable to us (Dhennin et al., ; Pltonikov et al., ; Tekerlekov et al., ). To date, the clinical quantification of lesions at the inoculation site and at the uninoculated feet and mouth remains the main method to evaluate protection in GP (Lucam et al., ; Bahnemann and Mesquita, ; Wu et al., ; Harmsen et al., ; Du et al., ,b; Guo et al., ). The objectives of this study were to (i) refine the FMDV‐infection model in GP by assessing both clinical and virological parameters of infection, (ii) assess the overall suitability of the GP model for the evaluation of small molecule inhibitors of the FMDV replication using T‐1105 as a reference and (iii) compare the protection offered by the antiviral drug with that conferred by an oil‐adjuvanted FMD vaccine.…”

Section: Introductionmentioning

confidence: 99%

A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds

Vleeschauwer

Lefebvre

Willems

et al. 2014

Transbound Emerg Dis

View full text Add to dashboard Cite

An antiviral containment strategy for foot-and-mouth disease (FMD) outbreaks could support or replace current contingency plans in case of an outbreak in Europe and could spare many healthy animals from being pre-emptively culled. Recently, substantial progress has been made towards the development of small molecule drugs that inhibit FMD virus (FMDV) replication in vitro. For the initial in vivo evaluation of antiviral lead molecules, a refined FMDV-infection model in guinea pigs (GP) is herewith described. This GP model was validated by demonstrating the antiviral effect of T-1105 (an influenza virus inhibitor with reported activity against FMDV). Sixteen animals were orally administered with T-1105 twice daily (400 mg/kg/day) for five consecutive days and inoculated intraplantarly with 100 GPID50 of the GP-adapted FMDV strain O1 Manisa 1 h after the first administration. The efficacy of T-1105 was compared with that of prophylactic vaccination with a highly potent double-oil emulsion-inactivated O1 Manisa vaccine. Ten animals received a single, full (2 ml) cattle vaccine dose and were inoculated 3 weeks later. Fourteen T-1105-treated and all vaccinated GP were completely protected from generalization of vesicular lesions. At 2 dpi, viral RNA was detected in serum of 9/16 T-1105-treated and of 6/10 vaccinated animals. At 4 dpi, viral RNA was detected in serum, organs and oral swabs of half of the T-1105-treated animals and only in the serum of 1/10 of the vaccinated animals. Mean viral RNA levels in serum and organs of T-1105-treated and vaccinated animals were reduced compared to untreated controls (P < 0.01). T-1105 conferred a substantial clinical and virological protection against infection with O1 Manisa, similar to the protection afforded by vaccination. These results validate the suitability of the enhanced GP model for the purpose of initial evaluation of inhibitors of FMDV replication and illustrate the potential of selective inhibitors of viral replication to control FMD outbreaks.

show abstract

Section: Introductionmentioning

confidence: 99%

A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds

Vleeschauwer

Lefebvre

Willems

et al. 2014

Transbound Emerg Dis

View full text Add to dashboard Cite

show abstract

“…Although the correlation between FMDV NA titer and protective efficacy in cattle has been well established [32-34], previous studies have shown that the protection against FMD is related not only to humoral immunity, but also to cellular immunity [35-37]. Previous studies have also shown that swine immunized with recombinant adenovirus expressing FMDV VP1 were completely protected against virulent FMDV challenge, even though the NA (titer < 40) induced by recombinant adenovirus expressing FMDV VP1 was significantly lower than that in swine inoculated with inactivated FMD vaccine [38,39]. Also, other reports showed that swine or cattle immunized with adenovirus expressing the FMDV P1 protein were protected against virulent FMDV challenge at post-vaccination day 7, although an NA titer was undetectable [28,40].…”

Section: Discussionmentioning

confidence: 99%

Induction of protective immune response against both PPRV and FMDV by a novel recombinant PPRV expressing FMDV VP1

Yin

Chen

et al. 2014

Vet Res

View full text Add to dashboard Cite

Peste des petits ruminants (PPR) and foot-and-mouth disease (FMD) are both highly contagious diseases of small domestic and wild ruminants caused by the PPR virus (PPRV) and the FMD virus (FMDV). In this study, a recombinant PPRV expressing the FMDV VP1 gene (rPPRV/VP1) was generated and FMDV VP1 expression did not impair replication of the recombinant virus in vitro and immunogenicity in inducing neutralizing antibody against PPR in goats. Vaccination with one dose of rPPRV/VP1 induced FMDV neutralizing antibody in goats and protected them from challenge with virulent FMDV. Our results suggest that the recombinant PPRV expressing the FMDV VP1 protein is a potential dual live vectored vaccine against PPRV and FMDV.

show abstract

“…In addition, it has been reported that IFN‐α can function as an adjuvant when co‐administered with an antigen including soluble protein (27), killed vaccine (28), or DNA encoding a transgene (29). Immunization of FMDV antigen with IFN‐α induced significantly higher titers of neutralizing antibodies and higher levels of T‐cell proliferation and IFN‐γ than antigen alone (30). Alternatively, IFN‐γ, the only type II IFN, is an important cytokine produced primarily by T lymphocytes and NK cells that play a role in modulation of the immune responses.…”

Section: Discussionmentioning

confidence: 99%

Co‐administration of live attenuated Salmonella enterica serovar Typhimurium expressing swine interleukin‐18 and interferon‐α provides enhanced Th1‐biased protective immunity against inactivated vaccine of pseudorabies virus

Kim

Han

et al. 2012

Microbiology and Immunology

View full text Add to dashboard Cite

The co-administration of two or more cytokines may generate additive or synergistic effects for controlling infectious diseases. However, the practical use of cytokine combinations for the modulation of immune responses against inactivated vaccine has not been demonstrated in livestock yet, primarily due to protein stability, production, and costs associated with mass administration. In light of the current situation, we evaluated the immunomodulatory functions of the combined administration of swine interleukin-18 (swIL-18) and interferon-α (swIFN-α) against an inactivated PrV vaccine using attenuated Salmonella enterica serovar Typhimurium as a cytokine delivery system. Co-administration of S. enterica serovar Typhimurium expressing swIL-18 and swIFN-α produced enhanced Th1-biased humoral and cellular immune responses against the inactivated PrV vaccine, when compared to single administration of S. enterica serovar Typhimurium expressing either swIL-18 or swIFN-α. Also, enhanced immune responses in co-administered piglets occurred rapidly after virulent PrV challenge, and piglets that received coadministration of S. enterica serovar Typhimurium expressing swIL-18 and swIFN-α displayed a greater alleviation of clinical severity following the virulent PrV challenge, as determined by clinical scores and cumulative daily weight gain. Furthermore, this enhancement was confirmed by reduced nasal shedding of PrV following viral challenge. Therefore, these results suggest that oral co-administration of S. enterica serovar Typhimurium expressing swIL-18 and swIFN-α provide enhanced Th1-biased immunity against inactivated PrV vaccine to alleviate clinical signs caused by PrV challenge.

show abstract

Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon α in mice and guinea pigs

Cited by 10 publications

References 33 publications

A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds

A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds

Induction of protective immune response against both PPRV and FMDV by a novel recombinant PPRV expressing FMDV VP1

Co‐administration of live attenuated Salmonella enterica serovar Typhimurium expressing swine interleukin‐18 and interferon‐α provides enhanced Th1‐biased protective immunity against inactivated vaccine of pseudorabies virus

Contact Info

Product

Resources

About